FR2937738B1 - USE OF ISOLATED POLYPEPTIDES HAVING ANTIGENIC PROPERTIES TO MYCOPLASMA PNEUMONIAE, AND CORRESPONDING POLYNUCLEOTIDES AND ANTIBODIES - Google Patents

USE OF ISOLATED POLYPEPTIDES HAVING ANTIGENIC PROPERTIES TO MYCOPLASMA PNEUMONIAE, AND CORRESPONDING POLYNUCLEOTIDES AND ANTIBODIES

Info

Publication number
FR2937738B1
FR2937738B1 FR0805874A FR0805874A FR2937738B1 FR 2937738 B1 FR2937738 B1 FR 2937738B1 FR 0805874 A FR0805874 A FR 0805874A FR 0805874 A FR0805874 A FR 0805874A FR 2937738 B1 FR2937738 B1 FR 2937738B1
Authority
FR
France
Prior art keywords
antibodies
isolated polypeptides
mycoplasma pneumoniae
antigenic properties
corresponding polynucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0805874A
Other languages
French (fr)
Other versions
FR2937738A1 (en
Inventor
Camille Cyncynatus
Helene Nuyttens
Julie Roge
Damien Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Victor Segalen Bordeaux 2
Diaxonhit SA
Original Assignee
Universite Victor Segalen Bordeaux 2
Abag SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Victor Segalen Bordeaux 2, Abag SA filed Critical Universite Victor Segalen Bordeaux 2
Priority to FR0805874A priority Critical patent/FR2937738B1/en
Priority to EP09760179A priority patent/EP2353009A2/en
Priority to PCT/FR2009/052000 priority patent/WO2010046592A2/en
Publication of FR2937738A1 publication Critical patent/FR2937738A1/en
Application granted granted Critical
Publication of FR2937738B1 publication Critical patent/FR2937738B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56933—Mycoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1253—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/30—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
FR0805874A 2008-10-23 2008-10-23 USE OF ISOLATED POLYPEPTIDES HAVING ANTIGENIC PROPERTIES TO MYCOPLASMA PNEUMONIAE, AND CORRESPONDING POLYNUCLEOTIDES AND ANTIBODIES Expired - Fee Related FR2937738B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR0805874A FR2937738B1 (en) 2008-10-23 2008-10-23 USE OF ISOLATED POLYPEPTIDES HAVING ANTIGENIC PROPERTIES TO MYCOPLASMA PNEUMONIAE, AND CORRESPONDING POLYNUCLEOTIDES AND ANTIBODIES
EP09760179A EP2353009A2 (en) 2008-10-23 2009-10-20 Use of isolated polypeptides having antigenic properties against mycoplasma pneumoniae, and of corresponding polynucleotides and antibodies
PCT/FR2009/052000 WO2010046592A2 (en) 2008-10-23 2009-10-20 Use of isolated polypeptides having antigenic properties against mycoplasma pneumoniae, and of corresponding polynucleotides and antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0805874A FR2937738B1 (en) 2008-10-23 2008-10-23 USE OF ISOLATED POLYPEPTIDES HAVING ANTIGENIC PROPERTIES TO MYCOPLASMA PNEUMONIAE, AND CORRESPONDING POLYNUCLEOTIDES AND ANTIBODIES

Publications (2)

Publication Number Publication Date
FR2937738A1 FR2937738A1 (en) 2010-04-30
FR2937738B1 true FR2937738B1 (en) 2013-02-15

Family

ID=40590576

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0805874A Expired - Fee Related FR2937738B1 (en) 2008-10-23 2008-10-23 USE OF ISOLATED POLYPEPTIDES HAVING ANTIGENIC PROPERTIES TO MYCOPLASMA PNEUMONIAE, AND CORRESPONDING POLYNUCLEOTIDES AND ANTIBODIES

Country Status (3)

Country Link
EP (1) EP2353009A2 (en)
FR (1) FR2937738B1 (en)
WO (1) WO2010046592A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014014897A2 (en) * 2012-07-16 2014-01-23 The Scripps Research Institute Immunoglobulin-binding human mycoplasma antigens and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7068587A (en) * 1986-03-27 1987-10-01 Cetus Corporation Monoclonal antibody immunoblot assay for antigens
US6537773B1 (en) * 1995-06-07 2003-03-25 The Institute For Genomic Research Nucleotide sequence of the mycoplasma genitalium genome, fragments thereof, and uses thereof
AUPN712795A0 (en) * 1995-12-13 1996-01-11 University Of Melbourne, The Recombinant vaccines
EP1678199B1 (en) * 2003-10-03 2013-03-20 The Board Of Regents, The University Of Texas System Methods and compositions for mycoplasma pneumoniae exotoxins

Also Published As

Publication number Publication date
WO2010046592A3 (en) 2010-06-24
WO2010046592A2 (en) 2010-04-29
FR2937738A1 (en) 2010-04-30
EP2353009A2 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
CY2017021I1 (en) HIGH Affinity HUMAN ANTIBODIES TO PCSK9
CY2017043I2 (en) ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION
BRPI0815603A2 (en) DETERMINATION OF CONTENT ITEM PRICE
ATE538137T1 (en) ANTIBODIES TO HUMAN IL-22 AND USES THEREOF
BRPI1012340A8 (en) specific binding proteins and uses thereof
DE112010004911A5 (en) Dual mass flywheel and clutch
BRPI0810744A2 (en) ABSORBENT OXYGEN MOLECULES, OBJECTS CONTAINING THEM, AND METHODS OF USE
BR112012002982A2 (en) use of modified stressed yeast extracts cosmetics and related compositions.
BRPI0907575A2 (en) Binding visual properties of charts and cells within tables
EP2331707A4 (en) Determining age ranges of skin samples
BRPI0915825A2 (en) prostaglandin binding proteins and uses thereof
FR2946879B1 (en) EXTRACT OF WHOLE SEEDS OF MORINGA SP. AND ITS USE IN COSMETIC AND / OR DERMATOLOGICAL COMPOSITIONS.
BR112013003564A2 (en) "dehydration sensor, absorbent article and insert for an absorbent personal care garment or product"
CL2012002898A1 (en) Pharmaceutical composition of fexofenadine comprising a granulated center and a layer of fat matrix coating in addition to binder, lubricant, diluent; Your preparation procedure.
BRPI0814644A2 (en) CD200 ANTIBODIES AND USES OF THESE INHIBITING IMMUNE ANSWERS.
BR112013004486A2 (en) compositions comprising paulownina and / or extracts of paulonia and uses thereof
SG10201509984YA (en) Location-based information retrieval and analysis
FR2926020B1 (en) COSMETIC AND / OR DERMATOLOGICAL COMPOSITION
BRPI0907784A8 (en) regenerator configuration and methods with reduced steam demand
BRPI0913429A2 (en) canola protein isolate
ES2561330T9 (en) Composition comprising melissa extracts
FR2937738B1 (en) USE OF ISOLATED POLYPEPTIDES HAVING ANTIGENIC PROPERTIES TO MYCOPLASMA PNEUMONIAE, AND CORRESPONDING POLYNUCLEOTIDES AND ANTIBODIES
IT1398515B1 (en) IMPROVED PROCEDURE FOR ANALYSIS OF MATERIALS, PARTICULARLY CONSTRUCTION MATERIALS, AND DEVICE TO REALIZE THIS PROCEDURE
BRPI1013785A2 (en) optical sensor to identify and / or authenticate objects
FR2950530B1 (en) COSMETIC COMPOSITION COMPRISING TWO SEPARATE MERCAPTOSILOXANES, METHOD OF PERMANENT DEFORMATION OF HAIR AND USE

Legal Events

Date Code Title Description
CD Change of name or company name
TQ Partial transmission of property

Owner name: UNIVERSITE VICTOR SEGALEN BORDEAUX 2, FR

Effective date: 20150202

Owner name: DIAXONHIT, FR

Effective date: 20150202

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

ST Notification of lapse

Effective date: 20180629